Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anaphylaxis: recognition and management.
Arnold JJ, Williams PM. Arnold JJ, et al. Among authors: williams pm. Am Fam Physician. 2011 Nov 15;84(10):1111-8. Am Fam Physician. 2011. PMID: 22085665 Free article. Review.
Controlled Cord Traction During the Third Stage of Labor.
Culliney EM, Williams PM. Culliney EM, et al. Among authors: williams pm. Am Fam Physician. 2016 Mar 1;93(5):Online. Am Fam Physician. 2016. PMID: 26926982 Free article. Review. No abstract available.
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Alva AS, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: williams pm. JCO Precis Oncol. 2024 Apr;8:e2300406. doi: 10.1200/PO.23.00406. JCO Precis Oncol. 2024. PMID: 38603651 Clinical Trial.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
Gong J, Mita AC, Wei Z, Cheng HH, Mitchell EP, Wright JJ, Ivy SP, Wang V, Gray RC, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gong J, et al. Among authors: williams pm. JCO Precis Oncol. 2024 Apr;8:e2300407. doi: 10.1200/PO.23.00407. JCO Precis Oncol. 2024. PMID: 38603650 Clinical Trial.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Chen MF, et al. Among authors: williams pm. JCO Precis Oncol. 2024 Apr;8:e2300454. doi: 10.1200/PO.23.00454. JCO Precis Oncol. 2024. PMID: 38591867 Clinical Trial.
Tuberculosis - United States, 2023.
Williams PM, Pratt RH, Walker WL, Price SF, Stewart RJ, Feng PI. Williams PM, et al. MMWR Morb Mortal Wkly Rep. 2024 Mar 28;73(12):265-270. doi: 10.15585/mmwr.mm7312a4. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38547024 Free PMC article.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Connolly RM, Wang V, Hyman DM, Grivas P, Mitchell EP, Wright JJ, Sharon E, Gray RJ, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Wang J, Wisinski KB, Tricoli JV, Conley BA, Harris LN, Arteaga CL, O'Dwyer PJ, Chen AP, Flaherty KT. Connolly RM, et al. Among authors: williams pm. Clin Cancer Res. 2024 Apr 1;30(7):1273-1280. doi: 10.1158/1078-0432.CCR-23-0633. Clin Cancer Res. 2024. PMID: 38433347 Clinical Trial.
309 results